NextFlex podcast spotlights hybrid electronics for biotech including PDS Biotechnology; AVIXA InfoComm EDGE Dubai
- NextFlex explains design and scalable manufacturing that move prototypes into regulated production — vital for companies like PDS Biotechnology.
- Transition to regulated production is critical for PDS Biotechnology when integrating electronic monitoring, drug‑delivery interfaces, or diagnostics.
- Hybrid electronics help PDS Biotechnology integrate monitoring, drug‑delivery, and companion diagnostics with biologic therapies in medical settings.
Industry briefing: hybrid electronics meeting biotech needs
NextFlex launches podcast to explain hybrid electronics' path to market
NextFlex, the U.S. Hybrid Electronics Manufacturing Innovation Institute, is rolling out a new podcast series, Electronics at the Edge, to spotlight breakthroughs and commercial pathways in hybrid electronics. Episode one, "At the Edge of Innovation: What Are Hybrid Electronics?", features Executive Director Dr. Dan Gamota and frames hybrid electronics as reshaping the intersection of form, function and manufacturing. The series aims to make technical and programmatic lessons accessible while showing how collaboration accelerates commercialization across industry, government and academia.
The podcast foregrounds implications for the life sciences industry, where wearable sensors, point‑of‑care diagnostics and implantable devices increasingly rely on hybrid electronic assemblies. NextFlex hosts unpack how design choices and scalable manufacturing practices move prototypes into regulated production — a transition that companies such as PDS Biotechnology and other biotech firms find critical when integrating electronic monitoring, drug‑delivery interfaces or companion diagnostics with biologics. Guests and hosts discuss concrete examples of hybrid approaches applied to constrained form factors and harsh environments common in medical settings.
Later episodes map NextFlex’s consortium model and project‑call process, offering a playbook for multidisciplinary projects that bridge R&D and production. Episode two previews an overview of NextFlex’s commercial services with Dr. Scott Miller, and episode three examines how project calls drive results with Dr. Nick Morris. The series stresses measurable pathways from concept to market through networks, standards and manufacturing services, aiming to reduce technical risk and shorten timelines for commercialization of bioelectronic solutions relevant to biotech developers.
AVIXA stages experiential InfoComm EDGE in Dubai
AVIXA announces InfoComm EDGE, a two‑day experiential pro AV event at Dubai’s Festival Arena on Oct. 27–28, 2026, designed to let senior buyers see and experience integrated technology through live activations rather than traditional booths. The event targets stakeholders across government, enterprise, education and entertainment and invites integrators and manufacturers to submit designs and sponsorships.
Organisers say the format focuses on narrative‑led journeys and standards‑aligned showcases to help decision‑makers visualise complex solutions and reduce deployment risk. The Festival Arena offers more than 7,200 square metres of indoor and outdoor space and aims to pair local design and deployment communities with global buyers.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

